Kacie Law, PA
Medical · Louisville, KYNPI 1184004343
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 38.5% of the total.
Across 276 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- GSK$382
- Novo Nordisk$381
- AstraZeneca$369
- Amgen$255
- Pfizer$237
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,295100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 124 | $1,652 |
| GSK | 25 | $382 |
| Novo Nordisk | 24 | $381 |
| AstraZeneca | 22 | $369 |
| Amgen | 17 | $255 |
| Pfizer | 13 | $237 |
| Exact Sciences | 11 | $236 |
| Astellas Pharma US Inc | 2 | $140 |
| Lilly USA, LLC | 7 | $108 |
| Novartis | 5 | $84 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $69 |
| Boehringer Ingelheim | 3 | $49 |
| Sanofi Pasteur Inc. | 3 | $42 |
| Esperion Therapeutics, Inc. | 3 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Bayer | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Philips North America LLC | 1 | $21 |
| Johnson & Johnson | 1 | $19 |
| Abbott | 1 | $18 |
| Merck | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veozah$125
How this compares
$4,295 in reported general payments places this provider in the 80th percentile of 222 medical providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 61 | $55,438 |
| OzempicSemaglutide | 40 | $44,931 |
| EliquisApixaban | 53 | $42,373 |
| TrulicityDulaglutide | 18 | $29,811 |
| Repatha SureclickEvolocumab | 32 | $22,167 |
| JardianceEmpagliflozin | 18 | $20,975 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $16,427 |
| JanuviaSitagliptin Phosphate | 13 | $12,927 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $2,942 |
| Atorvastatin Calcium | 291 | $1,837 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 36 | $1,774 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $1,717 |
| Rosuvastatin Calcium | 186 | $1,542 |
| Nebivolol Hcl | 21 | $1,359 |
| Metoprolol Succinate | 106 | $1,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $369 | $58,38074 claims |
| Novo NordiskOzempic | $381 | $44,93140 claims |
| PfizerEliquis | $237 | $42,37353 claims |
| Lilly USA, LLCTrulicity | $108 | $29,81118 claims |
| Boehringer IngelheimJardiance | $49 | $20,97518 claims |
| GSKTrelegy Ellipta | $382 | $16,42714 claims |
| MerckJanuvia | $18 | $12,92713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 222 medical providers in Kentucky.
Other medical in Louisville
- Alexandra HuettLouisville$13K
- Mitzi CarterLouisville$5K
- Kristen YoungLouisville$5K
- Lindsey KraftLouisville$4K
- Elizabeth ArnoldLouisville$3K
- Kristen HordLouisville$3K
- William BriggsLouisville$3K
- Mikal BaileyPaducah$84K
- Kyle HeraldBowling Green$65K
- Chasity HesterLexington$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.